Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.

IF 4 3区医学 Q2 ONCOLOGY

Targeted Oncology Pub Date : 2026-04-21 DOI:10.1007/s11523-026-01210-7

Sheridan M Hoy

{"title":"Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.","authors":"Sheridan M Hoy","doi":"10.1007/s11523-026-01210-7","DOIUrl":null,"url":null,"abstract":"Isatuximab (isatuximab-irfc; SARCLISA®) is an anti-CD38 monoclonal antibody approved in the EU and the USA for use in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (ASCT). In a phase III study in this patient population, isatuximab-bortezomib-lenalidomide-dexamethasone significantly prolonged progression-free survival (PFS) and generally improved the depth of tumour response versus bortezomib-lenalidomide-dexamethasone. Overall survival (OS) data were immature at the time of this analysis. Health-related quality of life was not affected by adding isatuximab to bortezomib-lenalidomide-dexamethasone. Only a slight increase in toxicity resulted from the addition of isatuximab to bortezomib-lenalidomide-dexamethasone, with the safety findings from the study consistent with the known safety profile of isatuximab-bortezomib-lenalidomide-dexamethasone. Although further interim and final PFS and OS data are awaited, current evidence indicates that isatuximab-bortezomib-lenalidomide-dexamethasone is a useful addition to the treatment options available for adults with NDMM who are ineligible for ASCT.","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Targeted Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11523-026-01210-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Isatuximab (isatuximab-irfc; SARCLISA^®) is an anti-CD38 monoclonal antibody approved in the EU and the USA for use in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (ASCT). In a phase III study in this patient population, isatuximab-bortezomib-lenalidomide-dexamethasone significantly prolonged progression-free survival (PFS) and generally improved the depth of tumour response versus bortezomib-lenalidomide-dexamethasone. Overall survival (OS) data were immature at the time of this analysis. Health-related quality of life was not affected by adding isatuximab to bortezomib-lenalidomide-dexamethasone. Only a slight increase in toxicity resulted from the addition of isatuximab to bortezomib-lenalidomide-dexamethasone, with the safety findings from the study consistent with the known safety profile of isatuximab-bortezomib-lenalidomide-dexamethasone. Although further interim and final PFS and OS data are awaited, current evidence indicates that isatuximab-bortezomib-lenalidomide-dexamethasone is a useful addition to the treatment options available for adults with NDMM who are ineligible for ASCT.

查看原文本刊更多论文

依沙妥昔单抗：对不适合移植的新诊断多发性骨髓瘤的研究综述。

Isatuximab （Isatuximab -irfc; SARCLISA®）是一种抗cd38单克隆抗体，已在欧盟和美国批准与硼替佐米、来那度胺和地塞米松联合使用，用于治疗不适合自体干细胞移植（ASCT）的新诊断多发性骨髓瘤（NDMM）成人患者。在该患者群体的一项III期研究中，与硼替佐米-来那度胺-地塞米松相比，isatuximah -硼替佐米-来那度胺-地塞米松相比，isatuximah -硼替佐米-来那度胺-地塞米松显着延长了无进展生存期（PFS），并普遍改善了肿瘤反应的深度。总生存期（OS）数据在本分析时尚不成熟。与健康相关的生活质量不受在硼替佐米-来那度胺-地塞米松中加入伊沙妥昔单抗的影响。在硼替佐米-来那度胺-地塞米松中加入伊沙妥昔单抗只会轻微增加毒性，研究的安全性结果与已知的伊沙妥昔单抗-硼替佐米-来那度胺-地塞米松的安全性一致。虽然等待进一步的中期和最终PFS和OS数据，但目前的证据表明，isatuximab-bortezomib-来那度胺-地塞米松是不符合ASCT条件的NDMM成人可用的治疗选择的有用补充。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Targeted Oncology 医学-肿瘤学

CiteScore

8.40

自引率

3.70%

发文量

审稿时长

>12 weeks

期刊介绍： Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes: Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches. Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways. Current Opinion articles that place interesting areas in perspective. Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations. Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement. Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.